The University of Michigan, including Michigan Medicine, is one of multiple institutions across the country that has received a federal subpoena as part of a criminal and civil investigation into gender-affirming care for minors. In light of that investigation, and given escalating external threats and risks, we will no longer provide gender affirming hormonal therapies and puberty blocker medications for minors.
We recognize the gravity and impact of this decision for our patients and our community. We are working closely with all those impacted, and we will continuously support the well-being of our patients, their families, and our teams.
We are deeply grateful to our clinicians for their unyielding commitment to providing the highest quality care, and to all of our team members for their dedication to helping our patients, and to supporting each other, as we navigate these changes together.
Media Contact
Public Relations
Department of Communication at Michigan Medicine
Featured News & Stories
U-M launches national search for next executive vice president for medical affairs and CEO of Michigan Medicine
Understanding family history key to early detection of pancreatic cancer
Patient with rare form of diabetes finds answers in genetic testing, clinical trials
How have diagnostic and treatment decisions for prostate cancer changed in recent years?
Small comforts make a world of difference
